NASDAQ:IMRN - Immuron Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$8.9455 -0.35 (-3.77 %)
(As of 05/23/2018 06:00 AM ET)
Previous Close$8.9455
Today's Range$8.86 - $9.25
52-Week Range$4.47 - $16.70
Volume2,550 shs
Average Volume11,289 shs
Market Capitalization$1.33 billion
P/E RatioN/A
Dividend YieldN/A
BetaN/A

About Immuron (NASDAQ:IMRN)

Immuron logoImmuron Limited, a biopharmaceutical company, focuses on the research and development of polyclonal antibodies for the treatment and prevention of various diseases in Australia and internationally. The company operates through Research and Development, and HyperImmune Products segments. It has a technology platform that produces antibodies to treat various diseases, including infectious diseases, cancers, and chronic inflammatory diseases. The company markets Travelan for the prevention of travellers' diarrhea. Its lead product candidate IMM-124E is in Phase II clinical trials for NASH and ASH. The company has a research and development collaboration agreement with the Walter Reed Army Institute of Research; and Naval Medical Research Center. Immuron Limited was founded in 1994 and is based in Blackburn North, Australia.

Receive IMRN News and Ratings via Email

Sign-up to receive the latest news and ratings for IMRN and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:IMRN
CUSIPN/A
Phone61-3-9824-5254

Debt

Debt-to-Equity RatioN/A
Current Ratio5.24
Quick Ratio3.32

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual Sales$1.05 million
Price / Sales1,216.42
Cash FlowN/A
Price / CashN/A
Book Value$0.04 per share
Price / Book223.64

Profitability

EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net MarginsN/A
Return on EquityN/A
Return on AssetsN/A

Miscellaneous

Employees7
Outstanding Shares142,780,000

Immuron (NASDAQ:IMRN) Frequently Asked Questions

What is Immuron's stock symbol?

Immuron trades on the NASDAQ under the ticker symbol "IMRN."

What price target have analysts set for IMRN?

1 analysts have issued 12 month price objectives for Immuron's shares. Their forecasts range from $20.00 to $20.00. On average, they anticipate Immuron's share price to reach $20.00 in the next year. View Analyst Ratings for Immuron.

Who are some of Immuron's key competitors?

Who are Immuron's key executives?

Immuron's management team includes the folowing people:
  • Dr. Jerry Kanellos Ph.D., Interim CEO (Age 57)
  • Mr. Peter Anastasiou, Exec. Vice Chairman (Age 58)
  • Mr. Phillip Allen Hains, Joint CFO & Company Sec. (Age 59)
  • Mr. Peter Vaughan BBus(Acc), CA, Joint CFO & Company Sec. (Age 35)
  • Mr. David Lyon, Head of Marketing

When did Immuron IPO?

(IMRN) raised $6 million in an initial public offering on Friday, June 9th 2017. The company issued 600,000 shares at a price of $9.99 per share. Joseph Gunnar and Rodman & Renshaw (a unit of H.C. Wainwright & Co.) served as the underwriters for the IPO and WallachBeth Capital was co-manager.

Has Immuron been receiving favorable news coverage?

News headlines about IMRN stock have been trending somewhat positive recently, according to Accern Sentiment Analysis. The research group identifies negative and positive media coverage by monitoring more than 20 million blog and news sources. Accern ranks coverage of companies on a scale of negative one to one, with scores nearest to one being the most favorable. Immuron earned a coverage optimism score of 0.14 on Accern's scale. They also gave media headlines about the company an impact score of 45.37 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the company's share price in the near future.

How do I buy shares of Immuron?

Shares of IMRN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Immuron's stock price today?

One share of IMRN stock can currently be purchased for approximately $8.9455.

How big of a company is Immuron?

Immuron has a market capitalization of $1.33 billion and generates $1.05 million in revenue each year. Immuron employs 7 workers across the globe.

How can I contact Immuron?

Immuron's mailing address is 25 37 CHAPMAN STREET, VICTORIA C3, 3130. The company can be reached via phone at 61-3-9824-5254 or via email at [email protected]


MarketBeat Community Rating for Immuron (IMRN)

Community Ranking:  2.7 out of 5 (star star)
Outperform Votes:  77 (Vote Outperform)
Underperform Votes:  64 (Vote Underperform)
Total Votes:  141
MarketBeat's community ratings are surveys of what our community members think about Immuron and other stocks. Vote "Outperform" if you believe IMRN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe IMRN will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Immuron (NASDAQ:IMRN) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
1 Wall Street analysts have issued ratings and price targets for Immuron in the last 12 months. Their average twelve-month price target is $20.00, suggesting that the stock has a possible upside of 123.58%. The high price target for IMRN is $20.00 and the low price target for IMRN is $20.00. There are currently 1 buy rating for the stock, resulting in a consensus rating of "Buy."
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 3.003.003.003.00
Ratings Breakdown: 0 Sell Rating(s)
0 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $20.00$20.00$15.00$15.00
Price Target Upside: 123.58% upside46.20% upside68.54% upside183.55% upside

Immuron (NASDAQ:IMRN) Consensus Price Target History

Price Target History for Immuron (NASDAQ:IMRN)

Immuron (NASDAQ:IMRN) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
3/9/2018HC WainwrightReiterated RatingBuy ➝ Buy$20.00HighView Rating Details
(Data available from 5/23/2016 forward)

Earnings

Dividends

Immuron (NASDAQ:IMRN) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

Immuron (NASDAQ IMRN) Insider Trading and Institutional Ownership History

Insider Trading History for Immuron (NASDAQ:IMRN)

Immuron (NASDAQ IMRN) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
(Data available from 1/1/2013 forward)

Headlines

Immuron (NASDAQ IMRN) News Headlines

Source:
DateHeadline
 Immuron (IMRN) Given Consensus Recommendation of "Strong Buy" by Analysts Immuron (IMRN) Given Consensus Recommendation of "Strong Buy" by Analysts
www.americanbankingnews.com - May 17 at 1:31 PM
Brokerages Anticipate Immuron (IMRN) to Post ($0.02) Earnings Per ShareBrokerages Anticipate Immuron (IMRN) to Post ($0.02) Earnings Per Share
www.americanbankingnews.com - May 2 at 3:22 PM
Zacks: Brokerages Set $20.00 Price Target for Immuron (IMRN)Zacks: Brokerages Set $20.00 Price Target for Immuron (IMRN)
www.americanbankingnews.com - April 16 at 5:31 AM
Immuron Limited - American Depositary Shares (IMRN) Coverage Initiated by Analysts at HC WainwrightImmuron Limited - American Depositary Shares (IMRN) Coverage Initiated by Analysts at HC Wainwright
www.americanbankingnews.com - April 6 at 4:17 PM
Zacks Investment Research Downgrades Immuron Limited - American Depositary Shares (IMRN) to HoldZacks Investment Research Downgrades Immuron Limited - American Depositary Shares (IMRN) to Hold
www.americanbankingnews.com - April 4 at 12:36 PM
Immuron Limited - American Depositary Shares (IMRN) Downgraded by ValuEngine to HoldImmuron Limited - American Depositary Shares (IMRN) Downgraded by ValuEngine to Hold
www.americanbankingnews.com - April 3 at 1:55 PM
Zacks: Immuron Limited - American Depositary Shares (IMRN) Given Consensus Recommendation of "Strong Buy" by BrokeragesZacks: Immuron Limited - American Depositary Shares (IMRN) Given Consensus Recommendation of "Strong Buy" by Brokerages
www.americanbankingnews.com - March 30 at 7:42 AM
Immuron Limited - American Depositary Shares (IMRN) Downgraded by Zacks Investment Research to "Hold"Immuron Limited - American Depositary Shares (IMRN) Downgraded by Zacks Investment Research to "Hold"
www.americanbankingnews.com - March 28 at 7:28 AM
Immuron Limited - American Depositary Shares (IMRN) Upgraded to Buy at Zacks Investment ResearchImmuron Limited - American Depositary Shares (IMRN) Upgraded to Buy at Zacks Investment Research
www.americanbankingnews.com - March 27 at 7:10 AM
Brokerages Anticipate Immuron Limited - American Depositary Shares (IMRN) to Announce ($0.02) EPSBrokerages Anticipate Immuron Limited - American Depositary Shares (IMRN) to Announce ($0.02) EPS
www.americanbankingnews.com - March 26 at 11:24 PM
Immuron Limited - American Depositary Shares (IMRN) Raised to "Buy" at Zacks Investment ResearchImmuron Limited - American Depositary Shares (IMRN) Raised to "Buy" at Zacks Investment Research
www.americanbankingnews.com - March 24 at 1:34 PM
Immuron Limited - American Depositary Shares (IMRN) Cut to "Hold" at Zacks Investment ResearchImmuron Limited - American Depositary Shares (IMRN) Cut to "Hold" at Zacks Investment Research
www.americanbankingnews.com - March 23 at 10:46 PM
 Analysts Set $20.00 Price Target for Immuron Limited - American Depositary Shares (IMRN) Analysts Set $20.00 Price Target for Immuron Limited - American Depositary Shares (IMRN)
www.americanbankingnews.com - March 23 at 1:32 AM
Immuron Announces A$5.1M Private Placement to U.S. FundImmuron Announces A$5.1M Private Placement to U.S. Fund
finance.yahoo.com - March 14 at 10:45 AM
Immuron Progresses Discussions with Institutional FundsImmuron Progresses Discussions with Institutional Funds
finance.yahoo.com - March 13 at 10:02 AM
Your Daily Pharma Scoop: Immuron Surges, MyoKardia Results, Voyager Reports Longer-Term Data For VY-AADCYour Daily Pharma Scoop: Immuron Surges, MyoKardia Results, Voyager Reports Longer-Term Data For VY-AADC
seekingalpha.com - March 10 at 5:07 PM
HC Wainwright Analysts Give Immuron Limited - American Depositary Shares (IMRN) a $20.00 Price TargetHC Wainwright Analysts Give Immuron Limited - American Depositary Shares (IMRN) a $20.00 Price Target
www.americanbankingnews.com - March 9 at 10:54 PM
Immuron Limited Issues Correction to Misleading Halt Announcement HeadlineImmuron Limited Issues Correction to Misleading Halt Announcement Headline
finance.yahoo.com - March 8 at 10:05 AM
Immuron Reports Positive Results in NASH Clinical TrialImmuron Reports Positive Results in NASH Clinical Trial
finance.yahoo.com - March 8 at 10:05 AM
Travelan® Revenue Grows Significantly in US and AustraliaTravelan® Revenue Grows Significantly in US and Australia
finance.yahoo.com - February 16 at 4:26 PM
HC Wainwright Reaffirms "Buy" Rating for Immuron Limited - American Depositary Shares (IMRN)HC Wainwright Reaffirms "Buy" Rating for Immuron Limited - American Depositary Shares (IMRN)
www.americanbankingnews.com - February 1 at 1:52 PM
Immuron Enrols First Patients in Clinical Study of IMM-529 for Treatment of Clostridium Difficile Infection (CDI)Immuron Enrols First Patients in Clinical Study of IMM-529 for Treatment of Clostridium Difficile Infection (CDI)
finance.yahoo.com - January 31 at 4:39 PM
US Defense Reports Broad Travelan® Reactivity to 180 Pathogenic Bacteria Including Camylobacter and ShigellaUS Defense Reports Broad Travelan® Reactivity to 180 Pathogenic Bacteria Including Camylobacter and Shigella
finance.yahoo.com - January 29 at 4:33 PM
Immuron to Receive $2.16M R&D Tax Concession RefundImmuron to Receive $2.16M R&D Tax Concession Refund
finance.yahoo.com - January 24 at 4:55 PM
CEO to Present on US Investor TV Show and at Biotech ConferenceCEO to Present on US Investor TV Show and at Biotech Conference
finance.yahoo.com - January 10 at 9:04 AM
Immuron to Present at RedChip’s Global Online Growth ConferenceImmuron to Present at RedChip’s Global Online Growth Conference
finance.yahoo.com - December 6 at 9:08 AM
Immuron Ltds (IMRN) Lock-Up Period Will End  on December 6thImmuron Ltd's (IMRN) Lock-Up Period Will End on December 6th
www.americanbankingnews.com - November 29 at 1:34 AM
Van Leeuwenhoeck Institute Updates Immuron Research CoverageVan Leeuwenhoeck Institute Updates Immuron Research Coverage
finance.yahoo.com - November 23 at 2:19 AM
HC Wainwright Reiterates "Buy" Rating for Immuron Ltd (IMRN)HC Wainwright Reiterates "Buy" Rating for Immuron Ltd (IMRN)
www.americanbankingnews.com - November 20 at 7:41 AM
Immuron Granted US Patent for NASH TreatmentImmuron Granted US Patent for NASH Treatment
finance.yahoo.com - November 17 at 6:33 AM
Immuron Successfully Completes NASH Phase II Clinical Study MilestoneImmuron Successfully Completes NASH Phase II Clinical Study Milestone
finance.yahoo.com - November 11 at 12:12 PM
Travelan Experiences Strong Q1 FY2018 Sales GrowthTravelan Experiences Strong Q1 FY2018 Sales Growth
finance.yahoo.com - November 8 at 10:17 AM
Immuron Commences US Non-Deal Institutional Investor RoadshowImmuron Commences US Non-Deal Institutional Investor Roadshow
finance.yahoo.com - September 19 at 7:56 PM
Immuron Highlights Recent Milestones in Quest to Effectively Treat Multiple Forms of Fatty Liver Diseases That Impact MillionsImmuron Highlights Recent Milestones in Quest to Effectively Treat Multiple Forms of Fatty Liver Diseases That Impact Millions
finance.yahoo.com - September 19 at 7:56 PM
Immuron Approved to Commence Clinical Study in C.Difficile Infection (CDI)Immuron Approved to Commence Clinical Study in C.Difficile Infection (CDI)
finance.yahoo.com - August 9 at 8:07 PM
Immuron Ltds Quiet Period Will End  on July 19th (NASDAQ:IMRN)Immuron Ltd's Quiet Period Will End on July 19th (NASDAQ:IMRN)
www.americanbankingnews.com - July 12 at 8:32 AM
NASH Phase II Interim Analysis Reveals Improvement in Liver Enzymes (AST and ALT) with Good Safety and TolerabilityNASH Phase II Interim Analysis Reveals Improvement in Liver Enzymes (AST and ALT) with Good Safety and Tolerability
finance.yahoo.com - July 10 at 7:51 PM

SEC Filings

Immuron (NASDAQ:IMRN) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Financials are not available for this stock.

Chart

Immuron (NASDAQ IMRN) Stock Chart for Wednesday, May, 23, 2018

Loading chart…

This page was last updated on 5/23/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.